Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 3,027 shares, an increase of 195.3% from the January 15th total of 1,025 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average trading volume of 53,704 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 53,704 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aptorum Group in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Aptorum Group Price Performance

NASDAQ APM opened at $0.78 on Friday. The company’s 50 day moving average is $1.04 and its 200-day moving average is $1.45. Aptorum Group has a 12-month low of $0.65 and a 12-month high of $4.47.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.